Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - UNIGENE LABORATORIES INC | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 24, 2011
___________
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-16005
|
22-2328609
|
|
(State or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
81 Fulton Street, Boonton, New Jersey
|
07005
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(973) 265-1100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 8 – Other Events
Item 8.01 Other Events.
On June 24, 2011, Unigene Laboratories, Inc. (the “Company”) presented positive preclinical data for UPG281, the Company’s orally-delivered anorexigenic peptide, in a late-breaking poster presentation at the American Diabetes Association 71st Scientific Sessions. On June 27, 2011, the Company issued a press release summarizing this presentation. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Document Description
|
|
99.1
|
Press Release dated June 27, 2011
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UNIGENE LABORATORIES, INC.
|
|||
|
By:
|
/s/ Jenene D. Thomas | ||
| Jenene D. Thomas, Vice President | |||
| Investor Relations and Corporate Communications | |||
|
Date: June 27, 2011
|
|||
EXHIBIT INDEX
|
Exhibit No.
|
Document Description
|
|
99.1
|
Press Release dated June 27, 2011
|